Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1053073.RAV_FYVPfV30EbuuzLuejyVd4omf8TsAKyV4bUAinkiJ0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1053073.RAV_FYVPfV30EbuuzLuejyVd4omf8TsAKyV4bUAinkiJ0130_assertion type Assertion NP1053073.RAV_FYVPfV30EbuuzLuejyVd4omf8TsAKyV4bUAinkiJ0130_head.
- NP1053073.RAV_FYVPfV30EbuuzLuejyVd4omf8TsAKyV4bUAinkiJ0130_assertion description "[As evaluated by MTT assays, gefitinib (EGFR inhibitor) and DIM-C (PPAR? agonist) inhibited growth of 9 bladder cancer cell lines in a dose-dependent manner but with variable sensitivity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1053073.RAV_FYVPfV30EbuuzLuejyVd4omf8TsAKyV4bUAinkiJ0130_provenance.
- NP1053073.RAV_FYVPfV30EbuuzLuejyVd4omf8TsAKyV4bUAinkiJ0130_assertion evidence source_evidence_literature NP1053073.RAV_FYVPfV30EbuuzLuejyVd4omf8TsAKyV4bUAinkiJ0130_provenance.
- NP1053073.RAV_FYVPfV30EbuuzLuejyVd4omf8TsAKyV4bUAinkiJ0130_assertion SIO_000772 23409107 NP1053073.RAV_FYVPfV30EbuuzLuejyVd4omf8TsAKyV4bUAinkiJ0130_provenance.
- NP1053073.RAV_FYVPfV30EbuuzLuejyVd4omf8TsAKyV4bUAinkiJ0130_assertion wasDerivedFrom befree-2016 NP1053073.RAV_FYVPfV30EbuuzLuejyVd4omf8TsAKyV4bUAinkiJ0130_provenance.
- NP1053073.RAV_FYVPfV30EbuuzLuejyVd4omf8TsAKyV4bUAinkiJ0130_assertion wasGeneratedBy ECO_0000203 NP1053073.RAV_FYVPfV30EbuuzLuejyVd4omf8TsAKyV4bUAinkiJ0130_provenance.